CDK4/6 play a key role in cell‐cycle progression by phosphorylating and inactivating the retinoblastoma protein, a tumour suppressor that restrains G1‐to S‐phase progression.25 Rapidly emerging data with selective inhibitors of CDK4/6 have validated these cell‐cycle kinases as anticancer drug targets, corroborating longstanding preclinical predictions.26, 27 In this study, we found that stable depletion of TRIM59 with shRNA in A549 and H1299 cells strongly inhibited CDK6 expression. Here, CDK4 is linked to neoplasm.